Samaha Eli 4

What Happened Eli Samaha, a reported 10% owner and managing partner of Madison Avenue Partners, LP, sold a total of 336,697 shares of Theravance Biopharma in three open-market/private-sale transactions, generating roughly $5.79 million in proceeds. The trades were reported on a Form 4 filed July 1, 2026, covering transactions on June 29, June 30 and July 1, 2026. Sales are typically routine transactions and do not necessarily signal a change in company outlook.

Key Details

• Transactions:
  • 2026-06-29: 273,871 shares at a weighted average $17.23 — proceeds $4,720,139 (price range reported: $17.07–$17.30) [F1]
  • 2026-06-30: 25,027 shares at a weighted average $17.13 — proceeds $428,788 (price range reported: $17.13–$17.145) [F2]
  • 2026-07-01: 37,799 shares at a weighted average $17.00 — proceeds $642,628 (price range reported: $17.00–$17.015) [F3]
• Total sold: 336,697 shares for approximately $5,791,555.
• Shares owned after the transaction: not specified in the provided filing.
• Filing: Form 4 filed 2026-07-01 (no indication in the filing that it was late).
• Footnote on ownership: the shares are held by funds managed by Madison Avenue Partners, LP; Samaha is the managing partner and disclaims beneficial ownership except for his pecuniary interest [F4].

Context These were sale transactions by a large (10%) reported owner and appear to be disposals of fund-held shares rather than executive compensation exercises or gifts. Sales by institutional principals can reflect portfolio rebalancing or liquidity needs and are generally less informative about company fundamentals than insider purchases. The filing’s footnotes clarify weighted-average pricing across multiple trades and the relationship between Samaha and the funds whose shares were sold.